Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H008 (Keverprazan) vs Esomeprazole in Peptic Ulcer Upper GI Bleeding
CTR20243040Phase 2Completed
- Sponsor
- Jiangsu Kefeiping Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of keverprazan in Peptic ulcer disease (PUD), upper gastrointestinal bleeding (UGIB), sponsored by Jiangsu Kefeiping Pharmaceutical Co., Ltd.. Started Aug 2024; status: completed.
02
Drugs
keverprazan
03
Conditions
Peptic ulcer disease (PUD)upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on CTR20243040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243040.